- Home >
- Investors
Investors
Our business model is designed to bring solutions to patients while generating shareholder value, by translating our proprietary technology into commercial drug products in a rapid and cost-effective way.
Investment case
Silence is the only listed RNAi player in Europe and a pioneer in this technology. Through the efforts of our skilled scientists over the years we have established a robust platform that allows us to effectively trigger RNAi in specific cell types. Our inventions are protected by a broad intellectual property estate, which is a fundamental asset. Together with our progress, the fact that the field is generally maturing means that RNAi drugs are close to becoming a powerful genetic medicine modality at the disposal of doctors and patients.
Results, reports & presentations
Annual Report 2019
DownloadHalf Year Results 2020
391KB DownloadFull Year Results 2019
361KB DownloadHalf Year Results 2019
345KB DownloadFull Year Results 2018
371KB DownloadHalf Year Results 2018
367KB DownloadAnnual Report 2019
1MB DownloadAnnual Report 2018
3MB DownloadAnnual Report 2017
2MB DownloadAnnual Report 2016
1MB DownloadAnnual Report 2015
978KB DownloadSilence Therapeutics FY19 Results Announcement
175KB DownloadCollaboration with AstraZeneca and R&D Update
176KB DownloadSilence Therapeutics HY20 Results Announcement
Click here to register for the webcast
955KB DownloadSilence Therapeutics Fireside Chat at the RBC Capital Markets Global Healthcare Virtual Conference
Click here to replay the webcast
163KB DownloadCorporate governance
Our Corporate Governance framework is based on using the leadership provided by our Board to drive the effective execution of our strategy, ensuring that risk is appropriately mitigated and managed.
We have three Board Committees (Remuneration, Audit and Risk, and Nominations), focused on providing the required oversight to maintaining the highest Corporate Governance standards. Through these committees and regular interactions with the executive team, our Board applies internal financial controls and approves the Company’s policy and strategy.